4//SEC Filing
SALIX PHARMACEUTICALS LTD 4
Accession 0001209191-14-003130
CIK 0001009356operating
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 5:05 PM ET
Size
14.2 KB
Accession
0001209191-14-003130
Insider Transaction Report
Form 4
D ALONZO THOMAS
Director
Transactions
- Exercise/Conversion
Common Stock
2014-01-10$18.87/sh+22,500$424,575→ 110,024 total - Sale
Common Stock
2014-01-10$91.83/sh−12,000$1,101,960→ 98,024 total - Sale
Common Stock
2014-01-10$92.85/sh−50$4,643→ 97,974 total - Exercise/Conversion
Option to Buy Common Stock
2014-01-10−22,500→ 0 totalExercise: $18.87Exp: 2014-06-17→ Common Stock (22,500 underlying)
Holdings
- 1,080(indirect: By Trust)
Common Stock
- 260(indirect: By LP)
Common Stock
- 6,500(indirect: By Spouse)
Common Stock
- 15,000
Option to Buy Common Stock
Exercise: $17.63Exp: 2015-06-09→ Common Stock (15,000 underlying)
Footnotes (4)
- [F1]The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2013.
- [F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.53 to $92.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The shares are held by the Rachel L. D'Alonzo Rev Trust U/A DTD 10/24/2001 for which the Reporting Person serves as co-trustee.
- [F4]Options are 100% vested.
Documents
Issuer
SALIX PHARMACEUTICALS LTD
CIK 0001009356
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001009356
Filing Metadata
- Form type
- 4
- Filed
- Jan 13, 7:00 PM ET
- Accepted
- Jan 14, 5:05 PM ET
- Size
- 14.2 KB